Table 3.

Clinical trials of HDACi and Pt drugs combination therapy

HDACi	Cancer target	Purpose	Gov. registration #	Patient population	Results	Clinical phase
SAHA (CDDP+Capecitabine)	Metastatic or Recurrent Gastric Cancer	Exploring the role of SAHA	NCT01045538	45	CR	I/II
VPA(Hydralazine)	Cervical cancer	Determining response rate, safety, biological effects	NCT00404326	17	Completed	II
Belinostat (CDDP+Etoposide)	Small cell lung carcinoma	Determining a safe, tolerable phase II dose	NCT00926640	39	CR	I
CUDC-101 (CDDP)	Head and neck	A dose escalation study	NCT01384799	22	CR	I
SAHA	Non-small cell lung cancer (non-SCLC)	determining the maximum tolerated dose	NCT01059552	22	CR	I
SAHA(CDDP+Isotrti noin+Combined chemotherapy)	Embryonal tumors (Brain and Central Nervous System Tumors)	Side effects of giving SAHA isotretino in together with chemotherapy	NCT00867178	62	CR	I
SAHA(CDDP+ Pemetrexed)	Advanced solid tumors	safety and tolerability	NCT00106626	52	Safety issues: Yes	I
MK0683 (CDDP+Gemcitabine)	Non-SCLC	safety and tolerability	NCT00423449	61	MTD 400 mg for up to 10 days in 21- day cycles Safety issues: Yes	I

Ref source: Clinicaltrials.gov

CDDP: Cisplatin, CR: Current, MTD: Maximum tolerated dose, SCLC: Small cell lung cancer